Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOVNYSE:GKOSNYSE:STVNNASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$31.86-1.3%$33.24$29.13▼$49.83$1.82B1.71832,306 shs1.37 million shsGKOSGlaukos$97.69+0.1%$92.76$77.10▼$163.71$5.58B0.8725,877 shs797,572 shsSTVNStevanato Group€23.40-2.5%€22.44€16.56▼€25.75$7.09B0.53337,852 shs466,100 shsTMDXTransMedics Group$142.88-0.1%$108.75$55.00▼$177.37$4.84B2.11.36 million shs455,068 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis-1.33%+0.22%-12.01%-13.92%-29.43%GKOSGlaukos+0.36%+5.00%+6.82%-4.63%-13.92%STVNStevanato Group-1.89%-1.68%-1.52%+17.71%+26.90%TMDXTransMedics Group-0.11%+2.75%+16.77%+108.49%+0.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENOVEnovis2.9416 of 5 stars3.42.00.00.02.31.71.9GKOSGlaukos4.4113 of 5 stars4.42.00.04.41.62.50.6STVNStevanato Group1.6842 of 5 stars0.04.01.70.01.50.01.9TMDXTransMedics Group1.2976 of 5 stars1.42.00.00.01.42.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.80Moderate Buy$58.0082.05% UpsideGKOSGlaukos 2.75Moderate Buy$134.6737.85% UpsideSTVNStevanato Group 2.86Moderate BuyN/AN/ATMDXTransMedics Group 2.80Moderate Buy$125.11-12.44% DownsideCurrent Analyst Ratings BreakdownLatest ENOV, STVN, GKOS, and TMDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.005/9/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.15B0.85$4.64 per share6.86$62.66 per share0.51GKOSGlaukos$404.52M13.80N/AN/A$9.46 per share10.33STVNStevanato Group$1.12B6.30€0.98 per share23.97€4.15 per share5.64TMDXTransMedics Group$488.23M9.90$0.27 per share530.08$4.20 per share34.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$33.26M-$13.95N/A9.99N/A-5.95%4.39%2.80%8/6/2025 (Estimated)GKOSGlaukos-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)STVNStevanato Group$157.62M€0.5149.7940.347.1810.47%9.86%5.79%N/ATMDXTransMedics Group-$25.03M$1.36152.0099.92N/A8.14%18.74%4.39%7/30/2025 (Estimated)Latest ENOV, STVN, GKOS, and TMDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/ASTVNStevanato Group€0.060.26%N/A11.76%1 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/ALatest ENOV, STVN, GKOS, and TMDX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.402.271.12GKOSGlaukos0.195.544.71STVNStevanato Group0.221.811.21TMDXTransMedics Group2.428.207.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%GKOSGlaukos99.04%STVNStevanato GroupN/ATMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipENOVEnovis2.70%GKOSGlaukos5.80%STVNStevanato Group0.70%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis6,80057.12 million55.49 millionOptionableGKOSGlaukos78057.14 million51.61 millionOptionableSTVNStevanato Group4,650302.84 million300.72 millionOptionableTMDXTransMedics Group21033.82 million31.21 millionOptionableENOV, STVN, GKOS, and TMDX HeadlinesRecent News About These CompaniesPrice Over Earnings Overview: TransMedics GroupJune 13 at 7:48 PM | benzinga.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12 at 3:11 PM | schaeffersresearch.comBronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities InvestigationJune 12 at 10:00 AM | accessnewswire.comMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayJune 12 at 7:53 AM | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $95,902.80 in StockJune 11 at 6:51 AM | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 686 Shares of StockJune 10, 2025 | marketbeat.comKuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law FirmJune 10, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the InvestigationJune 10, 2025 | accessnewswire.comTransMedics Group, Inc. (TMDX): A Bull Case TheoryJune 9, 2025 | insidermonkey.comTransMedics Group, Inc. (TMDX): A Bull Case TheoryJune 9, 2025 | finance.yahoo.com3 Medical Technology Stocks Outperforming in 2025 (TMDX)June 9, 2025 | marketbeat.comTransMedics: Data Points To Strong Second Quarter, But Beware Of The Second HalfJune 9, 2025 | seekingalpha.comGAMMA Investing LLC Boosts Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)June 9, 2025 | marketbeat.comTransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationJune 8, 2025 | accessnewswire.com12,523 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Two Sigma Investments LPJune 8, 2025 | marketbeat.comStocks With Rising Composite Ratings: TransMedics GroupJune 6, 2025 | msn.comTransMedics Group (NASDAQ:TMDX) Earns "Overweight" Rating from Piper SandlerJune 6, 2025 | americanbankingnews.com3 High-Growth Stocks Traders Love and Investors Should Watch (TMDX)June 5, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to ConnectJune 5, 2025 | accessnewswire.comSugar Maple Asset Management LLC Makes New $740,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)June 5, 2025 | marketbeat.comTransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLCJune 5, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayENOV, STVN, GKOS, and TMDX Company DescriptionsEnovis NYSE:ENOV$31.86 -0.43 (-1.33%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$31.91 +0.05 (+0.16%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Glaukos NYSE:GKOS$97.69 +0.09 (+0.09%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$97.77 +0.08 (+0.08%) As of 06/13/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Stevanato Group NYSE:STVN€23.40 -0.60 (-2.50%) As of 06/13/2025 03:58 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.TransMedics Group NASDAQ:TMDX$142.88 -0.16 (-0.11%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$143.47 +0.59 (+0.41%) As of 06/13/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
